Rezolute (NASDAQ:RZLT) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Rezolute (NASDAQ:RZLT) released its quarterly earnings results on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14), Zacks reports.

Rezolute Stock Up 5.4 %

NASDAQ:RZLT opened at $5.08 on Friday. The company has a market capitalization of $203.89 million, a PE ratio of -4.46 and a beta of 1.18. Rezolute has a 52-week low of $0.72 and a 52-week high of $6.10. The stock has a fifty day simple moving average of $4.62 and a 200-day simple moving average of $3.72.

Analyst Ratings Changes

A number of research firms have weighed in on RZLT. Craig Hallum assumed coverage on Rezolute in a research report on Tuesday, June 4th. They set a “buy” rating and a $14.00 price objective for the company. Guggenheim began coverage on Rezolute in a report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price target for the company. JMP Securities reissued a “market outperform” rating and issued a $7.00 price objective on shares of Rezolute in a research note on Friday. Maxim Group upped their price objective on shares of Rezolute from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, August 6th. Finally, BTIG Research lifted their target price on shares of Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $11.57.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.